1SBN_E_I;RI45K;RI38K;COR;Pr/PI;Pr/PI;3.2E-11;3.2E-11;5.4E-11;5.4E-11;1992167;Subtilisin BPN;Eglin c;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1SIB_E_I;KI53R;KI46R;INT;Pr/PI;Pr/PI;3.2E-11;3.2E-11;1.1E-10;1.1E-10;1992167;Subtilisin BPN;Eglin c;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1Y1K_E_I;AI58T;AI39T;COR;Pr/PI;Pr/PI;3E-12;3E-12;3E-10;3E-10;15865427;Subtilisin BPN;Chymotrypsin inhibitor 2;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1Y33_E_I;PI58T;PI39T;COR;Pr/PI;Pr/PI;3E-12;3E-12;1.7E-09;1.7E-09;15865427;Subtilisin BPN;Chymotrypsin inhibitor 2;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1Y34_E_I;AI60E;AI41E;COR;Pr/PI;Pr/PI;3E-12;3E-12;5.2E-10;5.2E-10;15865427;Subtilisin BPN;Chymotrypsin inhibitor 2;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1Y3B_E_I;SI60E;SI41E;COR;Pr/PI;Pr/PI;3E-12;3E-12;3.1E-10;3.1E-10;15865427;Subtilisin BPN;Chymotrypsin inhibitor 2;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


COR;Pr/PI;Pr/PI;3E-12;3E-12;1.2E-09;1.2E-09;15865427;Subtilisin BPN;Chymotrypsin inhibitor 2;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1Y3C_E_I;AI62R;AI43R;INT;Pr/PI;Pr/PI;3E-12;3E-12;2.5E-11;2.5E-11;15865427;Subtilisin BPN;Chymotrypsin inhibitor 2;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1Y48_E_I;AI65R;AI46R;INT;Pr/PI;Pr/PI;3E-12;3E-12;1.7E-09;1.7E-09;15865427;Subtilisin BPN;Chymotrypsin inhibitor 2;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1Y3D_E_I;AI67R;AI48R;INT;Pr/PI;Pr/PI;3E-12;3E-12;5.6E-10;5.6E-10;15865427;Subtilisin BPN;Chymotrypsin inhibitor 2;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1TM4_E_I;GI59M;GI40M;COR;Pr/PI;Pr/PI;3E-12;3E-12;1.3E-10;1.3E-10;15504027;Subtilisin BPN;Chymotrypsin inhibitor 2;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1TM5_E_I;AI59M;AI40M;COR;Pr/PI;Pr/PI;3E-12;3E-12;1.7E-11;1.7E-11;15504027;Subtilisin BPN;Chymotrypsin inhibitor 2;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1TM3_E_I;KI59M;KI40M;COR;Pr/PI;Pr/PI;3E-12;3E-12;1.9E-11;1.9E-11;15504027;Subtilisin BPN;Chymotrypsin inhibitor 2;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1TM7_E_I;YI59M;YI40M;COR;Pr/PI;Pr/PI;3E-12;3E-12;3.3E-12;3.3E-12;15504027;Subtilisin BPN;Chymotrypsin inhibitor 2;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1TMG_E_I;FI59M;FI40M;COR;Pr/PI;Pr/PI;3E-12;3E-12;1.7E-11;1.7E-11;15504027;Subtilisin BPN;Chymotrypsin inhibitor 2;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1TO1_E_I;AI61Y;AI42Y;COR;Pr/PI;Pr/PI;3E-12;3E-12;4.6E-10;4.6E-10;15504027;Subtilisin BPN;Chymotrypsin inhibitor 2;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1X1X_A_D;1.27E-07;1.27E-07;1.32E-10;1.32E-10;Water-mediated interaction at a protein-protein interface


1X1X_A_D;2.96E-06;2.96E-06;1.32E-10;1.32E-10;Water-mediated interaction at a protein-protein interface


1X1X_A_D;5.3E-10;5.3E-10;1.32E-10;1.32E-10;Water-mediated interaction at a protein-protein interface


1X1X_A_D;2.64E-10;2.64E-10;1.32E-10;1.32E-10;Water-mediated interaction at a protein-protein interface


1X1X_A_D;1.32E-10;1.32E-10;2.64E-10;2.64E-10;Water-mediated interaction at a protein-protein interface

2004;Barnase;Barstar;298;8.74E+05;8.74E+05;8.62E+05;8.62E+05;1.15E-04;1.15E-04;2.28E-04;2.28E-04;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1X1X_A_D;1.32E-10;1.32E-10;5.3E-10;5.3E-10;Water-mediated interaction at a protein-protein interface

2004;Barnase;Barstar;298;8.74E+05;8.74E+05;8.97E+05;8.97E+05;1.15E-04;1.15E-04;4.75E-04;4.75E-04;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1M9E_A_D;1.2E-05;1.2E-05;6.6E-05;6.6E-05;9223641;Cyclophilin A;HIV-1 capsid protein;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


3BT1_A_U;RU137A;RU135A;INT;;3BT1_A_U;5.6E-10;5.6E-10;9.1E-10;9.1E-10;10864923;Urokinase-type plasminogen activator;Urokinase plasminogen activator surface receptor;298;;;;;;;;;;;;;;SPR;1


3BT1_A_U;KU139A;KU137A;RIM;;3BT1_A_U;2.84E-09;2.84E-09;9.1E-10;9.1E-10;10864923;Urokinase-type plasminogen activator;Urokinase plasminogen activator surface receptor;298;;;;;;;;;;;;;;SPR;1


3BT1_A_U;RU142A;RU140A;SUR;;3BT1_A_U;1.68E-09;1.68E-09;9.1E-10;9.1E-10;10864923;Urokinase-type plasminogen activator;Urokinase plasminogen activator surface receptor;298;;;;;;;;;;;;;;SPR;1


3BT1_A_U;HU143A;HU141A;INT;;3BT1_A_U;2.78E-09;2.78E-09;9.1E-10;9.1E-10;10864923;Urokinase-type plasminogen activator;Urokinase plasminogen activator surface receptor;298;;;;;;;;;;;;;;SPR;1


3BT1_A_U;RU145A;RU143A;INT;;3BT1_A_U;1.85E-09;1.85E-09;9.1E-10;9.1E-10;10864923;Urokinase-type plasminogen activator;Urokinase plasminogen activator surface receptor;298;;;;;;;;;;;;;;SPR;1


1YQV_HL_Y;3E-07;3E-07;1E-09;1E-09;17405861;Inhibitor of vertebrate lysozyme;HEW Lysozyme;298;;;;;;;;;;;;;;IASP;1


1YQV_HL_Y;2E-08;2E-08;1E-09;1E-09;17405861;Inhibitor of vertebrate lysozyme;HEW Lysozyme;298;;;;;;;;;;;;;;IASP;1


1YQV_HL_Y;3E-09;3E-09;1E-09;1E-09;17405861;Inhibitor of vertebrate lysozyme;HEW Lysozyme;298;;;;;;;;;;;;;;IASP;1


2NOJ_A_B;1.4E-09;1.4E-09;6.21E-08;6.21E-08;18687868;Complement C3d;Fibrinogen-binding protein Efb-C;298;4.04E+05;4.04E+05;1.33E+06;1.33E+06;5.63E-04;5.63E-04;6.87E-02;6.87E-02;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


2NOJ_A_B;1.4E-09;1.4E-09;1.98E-08;1.98E-08;18687868;Complement C3d;Fibrinogen-binding protein Efb-C;298;4.04E+05;4.04E+05;1.2E+06;1.2E+06;5.63E-04;5.63E-04;2.14E-02;2.14E-02;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


2NOJ_A_B;2E-09;2E-09;2.6E-08;2.6E-08;18687868;Complement C3d;Fibrinogen-binding protein Efb-C;298;;;;;;;;;-8.5;-3.9;11.4;21.5;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


2NOJ_A_B;2E-09;2E-09;1.9E-08;1.9E-08;18687868;Complement C3d;Fibrinogen-binding protein Efb-C;298;;;;;;;;;-8.5;-5.5;11.4;16.8;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


2VIS_AB_C;IC131T;IC89T;COR;AB/AG;AB/AG;1E-09;1E-09;4E-06;4E-06;9461077;IgG1 lambda fab;Flu virus hemagglutinin;298;1.1E+05;1.1E+05;5.4E+02;5.4E+02;1.1E-04;1.1E-04;2.16E-03;2.16E-03;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


2WPT_A_B;3.26E-14;3.26E-14;1.68E-12;1.68E-12;18471830;Colicin E9 immunity protein;Colicin E9 DNase;298;7.24E+07;7.24E+07;1E+08;1E+08;2.36E-06;2.36E-06;1.68E-04;1.68E-04;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


2WPT_A_B;3.26E-14;3.26E-14;2.28E-11;2.28E-11;18471830;Colicin E9 immunity protein;Colicin E9 DNase;298;7.24E+07;7.24E+07;7.91E+07;7.91E+07;2.36E-06;2.36E-06;1.8E-03;1.8E-03;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


2WPT_A_B;1.62E-14;1.62E-14;5.46E-13;5.46E-13;9425068;Colicin E9 immunity protein;Colicin E9 DNase;298;1.13E+08;1.13E+08;2.6E+07;2.6E+07;1.83E-06;1.83E-06;1.42E-05;1.42E-05;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1KIQ_AB_C;FB101Y;FB101Y;COR;AB/AG;AB/AG;3.7E-09;3.7E-09;2.5E-07;2.5E-07;8952503;IgG1-kappa D1.3 Fv;HEW Lysozyme;298;;;;;;;;;-21.5;-14;-33.7;-17.3;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1KIP_AB_C;AB32Y;AB32Y;SUP;AB/AG;AB/AG;3.7E-09;3.7E-09;1.43E-08;1.43E-08;8952503;IgG1-kappa D1.3 Fv;HEW Lysozyme;298;;;;;;;;;-21.5;-17.2;-33.7;-22.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1KIR_AB_C;SA50Y;SA50Y;COR;AB/AG;AB/AG;3.7E-09;3.7E-09;3.85E-08;3.85E-08;8952503;IgG1-kappa D1.3 Fv;HEW Lysozyme;298;;;;;;;;;-21.5;-19.4;-33.7;-31.5;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


2PCB_A_B;1.4E-06;1.4E-06;1E-04;1E-04;16227441;Cytochrome C peroxidase;Cytochrome C;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


2PCB_A_B;1.4E-06;1.4E-06;1E-05;1E-05;16227441;Cytochrome C peroxidase;Cytochrome C;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


2PCB_A_B;1.4E-06;1.4E-06;5E-06;5E-06;16227441;Cytochrome C peroxidase;Cytochrome C;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


2PCB_A_B;1.4E-06;1.4E-06;2E-05;2E-05;16227441;Cytochrome C peroxidase;Cytochrome C;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


2JEL_LH_P;FP2Y;FP2Y;COR;AB/AG;AB/AG;3E-09;3E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;FP2W;FP2W;COR;AB/AG;AB/AG;2.5E-07;2.5E-07;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;QP3K;QP3K;COR;AB/AG;AB/AG;3E-06;3E-06;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;QP4K;QP4K;COR;AB/AG;AB/AG;3E-08;3E-08;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;EP5D;EP5D;RIM;AB/AG;AB/AG;6E-09;6E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;EP5Q;EP5Q;RIM;AB/AG;AB/AG;1E-08;1E-08;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;VP6F;VP6F;INT;AB/AG;AB/AG;3E-09;3E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;TP7N;TP7N;SUR;AB/AG;AB/AG;6E-09;6E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;TP7S;TP7S;SUR;AB/AG;AB/AG;3E-09;3E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;PP11E;PP11E;SUR;AB/AG;AB/AG;3E-09;3E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;NP12D;NP12D;SUR;AB/AG;AB/AG;3E-09;3E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;RP17G;RP17G;SUR;AB/AG;AB/AG;3E-09;3E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;RP17K;RP17K;SUR;AB/AG;AB/AG;3E-09;3E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;KP24E;KP24E;SUR;AB/AG;AB/AG;3E-09;3E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;KP27E;KP27E;SUR;AB/AG;AB/AG;3E-09;3E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;TP34N;TP34N;COR;AB/AG;AB/AG;>3E-04;3E-04;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;TP34Q;TP34Q;COR;AB/AG;AB/AG;3E-09;3E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;TP36Q;TP36Q;COR;AB/AG;AB/AG;6E-09;6E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;NP38T;NP38T;SUR;AB/AG;AB/AG;3E-09;3E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;SP43C;SP43C;SUR;AB/AG;AB/AG;3E-09;3E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;SP46C;SP46C;INT;AB/AG;AB/AG;3E-09;3E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;TP62N;TP62N;INT;AB/AG;AB/AG;3E-09;3E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;TP62A;TP62A;INT;AB/AG;AB/AG;3E-09;3E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;SP64T;SP64T;SUP;AB/AG;AB/AG;3E-06;3E-06;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;EP66K;EP66K;COR;AB/AG;AB/AG;>3E-06;3E-06;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;EP68A;EP68A;RIM;AB/AG;AB/AG;6E-09;6E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;EP70K;EP70K;SUP;AB/AG;AB/AG;>3E-06;3E-06;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;EP70A;EP70A;SUP;AB/AG;AB/AG;>3E-07;3E-07;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;QP71E;QP71E;COR;AB/AG;AB/AG;3E-07;3E-07;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;KP72R;KP72R;RIM;AB/AG;AB/AG;3E-09;3E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;KP72E;KP72E;RIM;AB/AG;AB/AG;6E-09;6E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;EP75R;EP75R;COR;AB/AG;AB/AG;3E-07;3E-07;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;HP76D;HP76D;RIM;AB/AG;AB/AG;1E-09;1E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;KP79E;KP79E;RIM;AB/AG;AB/AG;6E-09;6E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;AP82S;AP82S;SUR;AB/AG;AB/AG;3E-09;3E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;EP83A;EP83A;SUR;AB/AG;AB/AG;3E-09;3E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;EP85Q;EP85Q;SUR;AB/AG;AB/AG;3E-09;3E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;EP85D;EP85D;SUR;AB/AG;AB/AG;3E-09;3E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;EP85A;EP85A;SUR;AB/AG;AB/AG;3E-09;3E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2JEL_LH_P;EP85K;EP85K;SUR;AB/AG;AB/AG;3E-09;3E-09;3E-09;3E-09;1711212;Antibody Jel42;Histadine-containing protein HPr;298(assumed);;;;;;;;;;;;;Unusual method


2J0T_A_D;VD4A;VD4A;RIM;;2J0T_A_D;4E-10;4E-10;4E-10;4E-10;12515831;MMP1 Interstitial collagenase;Metalloproteinase inhibitor 1;298(assumed);;;;;;;;;;;;;;IAFL;1


RIM;;2J0T_A_D;1.4E-07;1.4E-07;4E-10;4E-10;12515831;MMP1 Interstitial collagenase;Metalloproteinase inhibitor 1;298(assumed);;;;;;;;;;;;;;IAFL;1


COR;;2J0T_A_D;3E-06;3E-06;4E-10;4E-10;12515831;MMP1 Interstitial collagenase;Metalloproteinase inhibitor 1;298(assumed);;;;;;;;;;;;;;IAFL;1


2J0T_A_D;TD2R;TD2R;COR;;2J0T_A_D;2E-06;2E-06;4E-10;4E-10;12515831;MMP1 Interstitial collagenase;Metalloproteinase inhibitor 1;298(assumed);;;;;;;;;;;;;;IAFL;1


RIM;;2J0T_A_D;3.3E-09;3.3E-09;4E-10;4E-10;12515831;MMP1 Interstitial collagenase;Metalloproteinase inhibitor 1;298(assumed);;;;;;;;;;;;;;IAFL;1


RIM;;2J0T_A_D;n.b;;4E-10;4E-10;12515831;MMP1 Interstitial collagenase;Metalloproteinase inhibitor 1;298(assumed);;;;;;;;;;;;;;IAFL;2


COR;;2J0T_A_D;1.5E-08;1.5E-08;4E-10;4E-10;12515831;MMP1 Interstitial collagenase;Metalloproteinase inhibitor 1;298(assumed);;;;;;;;;;;;;;IAFL;1


INT;;2J0T_A_D;1.8E-06;1.8E-06;1.5E-09;1.5E-09;9268350;MMP1 Interstitial collagenase;Metalloproteinase inhibitor 1;305;;;;;;;;;;;;;;IAFL;1


2J0T_A_D;TD2A;TD2A;COR;;2J0T_A_D;2.09E-06;2.09E-06;1.5E-09;1.5E-09;9268350;MMP1 Interstitial collagenase;Metalloproteinase inhibitor 1;305;;;;;;;;;;;;;;IAFL;1


2J0T_A_D;MD66A;MD66A;RIM;;2J0T_A_D;2.4E-08;2.4E-08;1.5E-09;1.5E-09;9268350;MMP1 Interstitial collagenase;Metalloproteinase inhibitor 1;305;;;;;;;;;;;;;;IAFL;1


2J0T_A_D;VD69I;VD69I;COR;;2J0T_A_D;5.7E-09;5.7E-09;1.5E-09;1.5E-09;9268350;MMP1 Interstitial collagenase;Metalloproteinase inhibitor 1;305;;;;;;;;;;;;;;IAFL;1


INT;;2J0T_A_D;4.9E-09;4.9E-09;1.5E-09;1.5E-09;9268350;MMP1 Interstitial collagenase;Metalloproteinase inhibitor 1;305;;;;;;;;;;;;;;IAFL;1


2BTF_A_P;FP59A;FP59A;COR;;2BTF_A_P;3.4E-05;3.4E-05;2.3E-06;2.3E-06;9788869;Bovine beta-actin;Bovine profilin;298(assumed);;;;;;;;;;;;;Methylated HIS73 has been reverted back to unmethylated form. Amino-terminal acetyl groups have been removed.


2BTF_A_P;VP60E;VP60E;RIM;;2BTF_A_P;1.2E-05;1.2E-05;2.3E-06;2.3E-06;9788869;Bovine beta-actin;Bovine profilin;298(assumed);;;;;;;;;;;;;Methylated HIS73 has been reverted back to unmethylated form. Amino-terminal acetyl groups have been removed.


2BTF_A_P;GP120F;GP120F;SUP;;2BTF_A_P;4.2E-05;4.2E-05;2.3E-06;2.3E-06;9788869;Bovine beta-actin;Bovine profilin;298(assumed);;;;;;;;;;;;;Methylated HIS73 has been reverted back to unmethylated form. Amino-terminal acetyl groups have been removed.


2BTF_A_P;KP125A;KP125A;COR;;2BTF_A_P;5E-06;5E-06;2.3E-06;2.3E-06;9788869;Bovine beta-actin;Bovine profilin;298(assumed);;;;;;;;;;;;;Methylated HIS73 has been reverted back to unmethylated form. Amino-terminal acetyl groups have been removed.


2ABZ_B_E;1.2E-07;1.2E-07;1.5E-09;1.5E-09;10691989;Carboxypeptidase A;Potato carboxypeptidase inhibitor;298(assumed);;;;;;;;;;;;;In chain I

as indicated by uniprot entries P01075 and Q9SBH8.


2ABZ_B_E;unf;;1.5E-09;1.5E-09;10691989;Carboxypeptidase A;Potato carboxypeptidase inhibitor;298(assumed);;;;;;;;;;;;;In chain I

as indicated by uniprot entries P01075 and Q9SBH8.


2ABZ_B_E;3.5E-09;3.5E-09;1.5E-09;1.5E-09;10691989;Carboxypeptidase A;Potato carboxypeptidase inhibitor;298(assumed);;;;;;;;;;;;;In chain I


2ABZ_B_E;1.5E-09;1.5E-09;1.5E-09;1.5E-09;10691989;Carboxypeptidase A;Potato carboxypeptidase inhibitor;298(assumed);;;;;;;;;;;;;In chain I


2ABZ_B_E;8.2E-07;8.2E-07;1.5E-09;1.5E-09;10691989;Carboxypeptidase A;Potato carboxypeptidase inhibitor;298(assumed);;;;;;;;;;;;;In chain I


2ABZ_B_E;7.6E-08;7.6E-08;1.5E-09;1.5E-09;8063780;Carboxypeptidase A;Potato carboxypeptidase inhibitor;298(assumed);;;;;;;;;;;;;In chain I


2ABZ_B_E;1.3E-08;1.3E-08;1.5E-09;1.5E-09;8063780;Carboxypeptidase A;Potato carboxypeptidase inhibitor;298(assumed);;;;;;;;;;;;;In chain I


2ABZ_B_E;2.1E-09;2.1E-09;1.5E-09;1.5E-09;8063780;Carboxypeptidase A;Potato carboxypeptidase inhibitor;298(assumed);;;;;;;;;;;;;In chain I


2ABZ_B_E;1.5E-09;1.5E-09;1.5E-09;1.5E-09;8063780;Carboxypeptidase A;Potato carboxypeptidase inhibitor;298(assumed);;;;;;;;;;;;;In chain I


3M63_A_B;2.9E-06;2.9E-06;3E-07;3E-07;10518943;UCH-L3;Ubiquitin;305;;;;;;;;;;;;;Receptor and ligand are covalently liked via vinyl-methy ester capped C-terminal of Ub. The modified residue is at the binding interface. The methyl 4-aminobutanoate fragment has been removed.


3M63_A_B;2.7E-07;2.7E-07;3E-07;3E-07;10518943;UCH-L3;Ubiquitin;305;;;;;;;;;;;;;Receptor and ligand are covalently liked via vinyl-methy ester capped C-terminal of Ub. The modified residue is at the binding interface. The methyl 4-aminobutanoate fragment has been removed.


3M63_A_B;7E-08;7E-08;3E-07;3E-07;10518943;UCH-L3;Ubiquitin;305;;;;;;;;;;;;;Receptor and ligand are covalently liked via vinyl-methy ester capped C-terminal of Ub. The modified residue is at the binding interface. The methyl 4-aminobutanoate fragment has been removed.


3M63_A_B;1.3E-06;1.3E-06;3E-07;3E-07;10518943;UCH-L3;Ubiquitin;305;;;;;;;;;;;;;Receptor and ligand are covalently liked via vinyl-methy ester capped C-terminal of Ub. The modified residue is at the binding interface. The methyl 4-aminobutanoate fragment has been removed.


3M63_A_B;3E-07;3E-07;3E-07;3E-07;10518943;UCH-L3;Ubiquitin;305;;;;;;;;;;;;;Receptor and ligand are covalently liked via vinyl-methy ester capped C-terminal of Ub. The modified residue is at the binding interface. The methyl 4-aminobutanoate fragment has been removed.


3M63_A_B;2.7E-06;2.7E-06;3E-07;3E-07;10518943;UCH-L3;Ubiquitin;305;;;;;;;;;;;;;Receptor and ligand are covalently liked via vinyl-methy ester capped C-terminal of Ub. The modified residue is at the binding interface. The methyl 4-aminobutanoate fragment has been removed.


3M63_A_B;1.66E-05;1.66E-05;3E-07;3E-07;10518943;UCH-L3;Ubiquitin;305;;;;;;;;;;;;;Receptor and ligand are covalently liked via vinyl-methy ester capped C-terminal of Ub. The modified residue is at the binding interface. The methyl 4-aminobutanoate fragment has been removed.


3M63_A_B;2E-07;2E-07;3E-07;3E-07;10518943;UCH-L3;Ubiquitin;305;;;;;;;;;;;;;Receptor and ligand are covalently liked via vinyl-methy ester capped C-terminal of Ub. The modified residue is at the binding interface. The methyl 4-aminobutanoate fragment has been removed.


3M63_A_B;1.5E-07;1.5E-07;3E-07;3E-07;10518943;UCH-L3;Ubiquitin;305;;;;;;;;;;;;;Receptor and ligand are covalently liked via vinyl-methy ester capped C-terminal of Ub. The modified residue is at the binding interface. The methyl 4-aminobutanoate fragment has been removed.


3M63_A_B;4E-06;4E-06;3E-07;3E-07;10518943;UCH-L3;Ubiquitin;305;;;;;;;;;;;;;Receptor and ligand are covalently liked via vinyl-methy ester capped C-terminal of Ub. The modified residue is at the binding interface. The methyl 4-aminobutanoate fragment has been removed.


3M63_A_B;5E-07;5E-07;3E-07;3E-07;10518943;UCH-L3;Ubiquitin;305;;;;;;;;;;;;;Receptor and ligand are covalently liked via vinyl-methy ester capped C-terminal of Ub. The modified residue is at the binding interface. The methyl 4-aminobutanoate fragment has been removed.


3M63_A_B;2.75E-05;2.75E-05;3E-07;3E-07;10518943;UCH-L3;Ubiquitin;305;;;;;;;;;;;;;Receptor and ligand are covalently liked via vinyl-methy ester capped C-terminal of Ub. The modified residue is at the binding interface. The methyl 4-aminobutanoate fragment has been removed.


3M63_A_B;3.2E-06;3.2E-06;3E-07;3E-07;10518943;UCH-L3;Ubiquitin;305;;;;;;;;;;;;;Receptor and ligand are covalently liked via vinyl-methy ester capped C-terminal of Ub. The modified residue is at the binding interface. The methyl 4-aminobutanoate fragment has been removed.


3M63_A_B;4.7E-07;4.7E-07;3E-07;3E-07;10518943;UCH-L3;Ubiquitin;305;;;;;;;;;;;;;Receptor and ligand are covalently liked via vinyl-methy ester capped C-terminal of Ub. The modified residue is at the binding interface. The methyl 4-aminobutanoate fragment has been removed.


3M63_A_B;1.97E-03;1.97E-03;6.35E-04;6.35E-04;12006492;Tumor susceptibility gene 101 protein;Ubiquitin;293;;;;;;;;;;;;;Selenomethionine residues reverted to methionine


3M63_A_B;8.89E-04;8.89E-04;6.35E-04;6.35E-04;12006492;Tumor susceptibility gene 101 protein;Ubiquitin;293;;;;;;;;;;;;;Selenomethionine residues reverted to methionine


3M63_A_B;5.08E-03;5.08E-03;6.35E-04;6.35E-04;12006492;Tumor susceptibility gene 101 protein;Ubiquitin;293;;;;;;;;;;;;;Selenomethionine residues reverted to methionine


3M63_A_B;3.24E-03;3.24E-03;6.35E-04;6.35E-04;12006492;Tumor susceptibility gene 101 protein;Ubiquitin;293;;;;;;;;;;;;;Selenomethionine residues reverted to methionine


3M63_A_B;1.02E-03;1.02E-03;6.35E-04;6.35E-04;12006492;Tumor susceptibility gene 101 protein;Ubiquitin;293;;;;;;;;;;;;;Selenomethionine residues reverted to methionine


3M63_A_B;2.35E-03;2.35E-03;6.35E-04;6.35E-04;12006492;Tumor susceptibility gene 101 protein;Ubiquitin;293;;;;;;;;;;;;;Selenomethionine residues reverted to methionine


1NCA_N_LH;NH31Q;NH31Q;COR;AB/AG;AB/AG;5E-08;5E-08;5E-08;5E-08;9692956;Subtype N9 neuraminidase;Antibody NC41 scFv;298(assumed);;;;;;;;;;;;;;FL;1


1NCA_N_LH;EH96D;EH100D;COR;AB/AG;AB/AG;1E-07;1E-07;5E-08;5E-08;9692956;Subtype N9 neuraminidase;Antibody NC41 scFv;298(assumed);;;;;;;;;;;;;;FL;1


INT;;1MQ8_A_B;1.5E-03;1.5E-03;3E-06;3E-06;12526797;Intercellular adhesion molecule I;Integrin alpha-L;298;3.1E+03;3.1E+03;1.33E+05;1.33E+05;4.6E+00;4.6E+00;4.3E-01;4.3E-01;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


SUR;;1MQ8_A_B;1.5E-07;1.5E-07;3E-06;3E-06;12526797;Intercellular adhesion molecule I;Integrin alpha-L;298;1.15E+05;1.15E+05;1.33E+05;1.33E+05;1.4E-02;1.4E-02;4.3E-01;4.3E-01;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


SUR;;1MQ8_A_B;3.6E-07;3.6E-07;3E-06;3E-06;12526797;Intercellular adhesion molecule I;Integrin alpha-L;298;1.05E+05;1.05E+05;1.33E+05;1.33E+05;4.5E-02;4.5E-02;4.3E-01;4.3E-01;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


SUR;;1MQ8_A_B;4.5E-04;4.5E-04;3E-06;3E-06;12526797;Intercellular adhesion molecule I;Integrin alpha-L;298;3.4E+03;3.4E+03;1.33E+05;1.33E+05;1.2E+00;1.2E+00;4.3E-01;4.3E-01;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


SUR;;1MQ8_A_B;1.6E-03;1.6E-03;3E-06;3E-06;12526797;Intercellular adhesion molecule I;Integrin alpha-L;298;2.3E+03;2.3E+03;1.33E+05;1.33E+05;3.6E+00;3.6E+00;4.3E-01;4.3E-01;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


SUR;;1MQ8_A_B;8.4E-06;8.4E-06;3E-06;3E-06;12526797;Intercellular adhesion molecule I;Integrin alpha-L;298;1.03E+05;1.03E+05;1.33E+05;1.33E+05;7.7E-01;7.7E-01;4.3E-01;4.3E-01;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


SUR;;1MQ8_A_B;9.4E-06;9.4E-06;3E-06;3E-06;12526797;Intercellular adhesion molecule I;Integrin alpha-L;298;8.9E+04;8.9E+04;1.33E+05;1.33E+05;7.6E-01;7.6E-01;4.3E-01;4.3E-01;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


3B4V_AB_C;3E-06;3E-06;7.3E-08;7.3E-08;19161338;Transforming growth factor beta 3;TGF-beta type II receptor;298(assumed);;;;;;;;;;;;;;SPR;1


3B4V_AB_C;8.9E-07;8.9E-07;7.3E-08;7.3E-08;19161338;Transforming growth factor beta 3;TGF-beta type II receptor;298(assumed);;;;;;;;;;;;;;SPR;1


3B4V_AB_C;9.5E-06;9.5E-06;7.3E-08;7.3E-08;19161338;Transforming growth factor beta 3;TGF-beta type II receptor;298(assumed);;;;;;;;;;;;;;SPR;1


1KTZ_A_B;2.8E-09;2.8E-09;9E-10;9E-10;15064755;Bone morphogenetic protein-2;BMPR-IA receptor;298(assumed);;;;;;;;;;;;;Mutations applied to A and B due to dimer


1KTZ_A_B;>7E-06;7E-06;9E-10;9E-10;15064755;Bone morphogenetic protein-2;BMPR-IA receptor;298(assumed);;;;;;;;;;;;;Mutations applied to A and B due to dimer


1KTZ_A_B;8E-10;8E-10;9E-10;9E-10;15064755;Bone morphogenetic protein-2;BMPR-IA receptor;298(assumed);;;;;;;;;;;;;Mutations applied to A and B due to dimer


1KTZ_A_B;4.8E-08;4.8E-08;9E-10;9E-10;15064755;Bone morphogenetic protein-2;BMPR-IA receptor;298(assumed);;;;;;;;;;;;;Mutations applied to A and B due to dimer


1KTZ_A_B;1.5E-08;1.5E-08;9E-10;9E-10;15064755;Bone morphogenetic protein-2;BMPR-IA receptor;298(assumed);;;;;;;;;;;;;Mutations applied to A and B due to dimer


1KTZ_A_B;7E-09;7E-09;9E-10;9E-10;15064755;Bone morphogenetic protein-2;BMPR-IA receptor;298(assumed);;;;;;;;;;;;;Mutations applied to A and B due to dimer


3QHY_A_B;4.77E-09;4.77E-09;2.8E-07;2.8E-07;15618400;TEM-1 beta-lactamase;BLIP;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


3QHY_A_B;4.77E-09;4.77E-09;1.66E-07;1.66E-07;15618400;TEM-1 beta-lactamase;BLIP;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


3QHY_A_B;9.85E-09;9.85E-09;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;6.61E+04;6.61E+04;6.7E+04;6.7E+04;3.19E-04;3.19E-04;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;2.21E-09;2.21E-09;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;1.12E+05;1.12E+05;6.7E+04;6.7E+04;1.16E-04;1.16E-04;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;1.2E-07;1.2E-07;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;6.43E+04;6.43E+04;6.7E+04;6.7E+04;4.03E-03;4.03E-03;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;9.43E-08;9.43E-08;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;1.79E+05;1.79E+05;6.7E+04;6.7E+04;8.67E-03;8.67E-03;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;2.5E-09;2.5E-09;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;1.75E+05;1.75E+05;6.7E+04;6.7E+04;2.01E-04;2.01E-04;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;1.66E-08;1.66E-08;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;4.06E+04;4.06E+04;6.7E+04;6.7E+04;3.35E-04;3.35E-04;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;4.22E-09;4.22E-09;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;7E+04;7E+04;6.7E+04;6.7E+04;1.78E-04;1.78E-04;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;2.4E-09;2.4E-09;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;2.65E+04;2.65E+04;6.7E+04;6.7E+04;2.96E-05;2.96E-05;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;1.06E-06;1.06E-06;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;2.58E+04;2.58E+04;6.7E+04;6.7E+04;1.52E-02;1.52E-02;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;1.15E-06;1.15E-06;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;5.79E+04;5.79E+04;6.7E+04;6.7E+04;3.7E-02;3.7E-02;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;8.03E-08;8.03E-08;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;6.95E+04;6.95E+04;6.7E+04;6.7E+04;2.9E-03;2.9E-03;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;2.4E-09;2.4E-09;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;3.58E+04;3.58E+04;6.7E+04;6.7E+04;3.92E-05;3.92E-05;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;1.59E-07;1.59E-07;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;9.82E+04;9.82E+04;6.7E+04;6.7E+04;8.27E-03;8.27E-03;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;8.73E-09;8.73E-09;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;6.3E+04;6.3E+04;6.7E+04;6.7E+04;4.05E-04;4.05E-04;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;7.68E-07;7.68E-07;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;7.68E+04;7.68E+04;6.7E+04;6.7E+04;3.22E-02;3.22E-02;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;3.59E-09;3.59E-09;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;1.04E+05;1.04E+05;6.7E+04;6.7E+04;1.74E-04;1.74E-04;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;3.29E-07;3.29E-07;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;6.5E+04;6.5E+04;6.7E+04;6.7E+04;9.8E-03;9.8E-03;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;4.93E-07;4.93E-07;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;5.17E+04;5.17E+04;6.7E+04;6.7E+04;1.4E-02;1.4E-02;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;6.26E-06;6.26E-06;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;2.46E+04;2.46E+04;6.7E+04;6.7E+04;9.08E-02;9.08E-02;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;2.03E-07;2.03E-07;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;3.34E+04;3.34E+04;6.7E+04;6.7E+04;4.5E-03;4.5E-03;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;2.48E-07;2.48E-07;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;6.43E+04;6.43E+04;6.7E+04;6.7E+04;9.4E-03;9.4E-03;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;1.06E-06;1.06E-06;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;1.38E+05;1.38E+05;6.7E+04;6.7E+04;8E-02;8E-02;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;3.03E-06;3.03E-06;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;2.17E+04;2.17E+04;6.7E+04;6.7E+04;3.81E-02;3.81E-02;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;2.68E-06;2.68E-06;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;7.61E+03;7.61E+03;6.7E+04;6.7E+04;1.14E-02;1.14E-02;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;1.66E-07;1.66E-07;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;9.22E+04;9.22E+04;6.7E+04;6.7E+04;8.11E-03;8.11E-03;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;7.36E-06;7.36E-06;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;2.53E+04;2.53E+04;6.7E+04;6.7E+04;1.1E-01;1.1E-01;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;6.83E-08;6.83E-08;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;5.03E+04;5.03E+04;6.7E+04;6.7E+04;1.77E-03;1.77E-03;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;1.59E-07;1.59E-07;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;6.04E+04;6.04E+04;6.7E+04;6.7E+04;5.17E-03;5.17E-03;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;6.01E-06;6.01E-06;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;2.62E+04;2.62E+04;6.7E+04;6.7E+04;9E-02;9E-02;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;2.11E-06;2.11E-06;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;2.54E+04;2.54E+04;6.7E+04;6.7E+04;2.99E-02;2.99E-02;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;8.73E-09;8.73E-09;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;5.49E+04;5.49E+04;6.7E+04;6.7E+04;2.27E-04;2.27E-04;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;2.19E-06;2.19E-06;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;1.32E+04;1.32E+04;6.7E+04;6.7E+04;1.6E-02;1.6E-02;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;4.2E-07;4.2E-07;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;4.63E+04;4.63E+04;6.7E+04;6.7E+04;1.03E-02;1.03E-02;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;1.6E-09;1.6E-09;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;1.2E+05;1.2E+05;6.7E+04;6.7E+04;8.75E-05;8.75E-05;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;2.69E-07;2.69E-07;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;3.06E+04;3.06E+04;6.7E+04;6.7E+04;4.34E-03;4.34E-03;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;1.07E-09;1.07E-09;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;2.39E+04;2.39E+04;6.7E+04;6.7E+04;1.16E-05;1.16E-05;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;2.37E-05;2.37E-05;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;4.29E+04;4.29E+04;6.7E+04;6.7E+04;1.25E-03;1.25E-03;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;1.03E-08;1.03E-08;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;6.3E+04;6.3E+04;6.7E+04;6.7E+04;6.08E-04;6.08E-04;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;1.11E-07;1.11E-07;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;9.26E+04;9.26E+04;6.7E+04;6.7E+04;5.29E-03;5.29E-03;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;1.87E-06;1.87E-06;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;5.05E+04;5.05E+04;6.7E+04;6.7E+04;5.19E-02;5.19E-02;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;6.28E-07;6.28E-07;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;8.34E+04;8.34E+04;6.7E+04;6.7E+04;2.87E-02;2.87E-02;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;4.91E-06;4.91E-06;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;2.22E+04;2.22E+04;6.7E+04;6.7E+04;9.33E-02;9.33E-02;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;5.56E-07;5.56E-07;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;9.2E+04;9.2E+04;6.7E+04;6.7E+04;2.81E-02;2.81E-02;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;1.95E-07;1.95E-07;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;6.33E+04;6.33E+04;6.7E+04;6.7E+04;6.48E-03;6.48E-03;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;5.34E-07;5.34E-07;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;5.08E+04;5.08E+04;6.7E+04;6.7E+04;1.46E-02;1.46E-02;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;1.66E-07;1.66E-07;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;4.18E+04;4.18E+04;6.7E+04;6.7E+04;3.59E-03;3.59E-03;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;6.83E-08;6.83E-08;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;5.03E+04;5.03E+04;6.7E+04;6.7E+04;1.77E-03;1.77E-03;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;1.79E-06;1.79E-06;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;2.02E+04;2.02E+04;6.7E+04;6.7E+04;4.12E-02;4.12E-02;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;2.29E-07;2.29E-07;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;6.13E+04;6.13E+04;6.7E+04;6.7E+04;7.31E-03;7.31E-03;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;6.83E-08;6.83E-08;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;4.57E+04;4.57E+04;6.7E+04;6.7E+04;1.57E-03;1.57E-03;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;5.34E-07;5.34E-07;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;5.44E+04;5.44E+04;6.7E+04;6.7E+04;1.65E-02;1.65E-02;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;4.91E-06;4.91E-06;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;2.66E+04;2.66E+04;6.7E+04;6.7E+04;7.7E-02;7.7E-02;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;2.39E-07;2.39E-07;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;1.57E+04;1.57E+04;6.7E+04;6.7E+04;2E-03;2E-03;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;4.53E-06;4.53E-06;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;2.38E+04;2.38E+04;6.7E+04;6.7E+04;6.83E-02;6.83E-02;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;3.72E-07;3.72E-07;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;5.59E+04;5.59E+04;6.7E+04;6.7E+04;1.1E-02;1.1E-02;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;6.05E-08;6.05E-08;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;7.31E+04;7.31E+04;6.7E+04;6.7E+04;2.29E-03;2.29E-03;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;8.03E-08;8.03E-08;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;3.81E+04;3.81E+04;6.7E+04;6.7E+04;1.58E-03;1.58E-03;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;1.95E-07;1.95E-07;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;2.16E+04;2.16E+04;6.7E+04;6.7E+04;2.17E-03;2.17E-03;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


3QHY_A_B;3.72E-07;3.72E-07;4.77E-09;4.77E-09;17070843;TEM-1 beta-lactamase;BLIP;298;1.1E+05;1.1E+05;6.7E+04;6.7E+04;2.58E-02;2.58E-02;1.5E-04;1.5E-04;;;;;SPR kinetic data provided by Gideon Schreiber. Mutations had greater effect when measured with stopped-flow fluorescence.;SPR;1


1GL0_E_I;MI30K;MI28K;COR;Pr/PI;Pr/PI;7.8E-10;7.8E-10;2E-09;2E-09;7592720;Bovine alpha-chymotrypsin;PMP-D2v insect inhibitor;298;1.4E+05;1.4E+05;1.03E+05;1.03E+05;1.1E-04;1.1E-04;2.1E-04;2.1E-04;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


COR;Pr/PI;Pr/PI;1.3E-06;1.3E-06;2E-09;2E-09;7592720;Bovine alpha-chymotrypsin;PMP-D2v insect inhibitor;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1FFW_A_B;DA13K;DA12K;SUR;;1FFW_A_B;1.3E-06;1.3E-06;1.2E-06;1.2E-06;7592655;Chemotaxis protein CheY;Chemotaxis protein CheA;298(assumed);;;;;;;;;;;;;;ELISA;1


1FFW_A_B;TA87I;TA86I;INT;;1FFW_A_B;7E-07;7E-07;1.2E-06;1.2E-06;7592655;Chemotaxis protein CheY;Chemotaxis protein CheA;298(assumed);;;;;;;;;;;;;;ELISA;1


1FFW_A_B;AA90V;AA89V;RIM;;1FFW_A_B;1.4E-06;1.4E-06;1.2E-06;1.2E-06;7592655;Chemotaxis protein CheY;Chemotaxis protein CheA;298(assumed);;;;;;;;;;;;;;ELISA;1


1FFW_A_B;EA93K;EA92K;SUR;;1FFW_A_B;4.8E-06;4.8E-06;1.2E-06;1.2E-06;7592655;Chemotaxis protein CheY;Chemotaxis protein CheA;298(assumed);;;;;;;;;;;;;;ELISA;1


1FFW_A_B;YA106W;YA105W;COR;;1FFW_A_B;4E-06;4E-06;1.2E-06;1.2E-06;7592655;Chemotaxis protein CheY;Chemotaxis protein CheA;298(assumed);;;;;;;;;;;;;;ELISA;1


1FFW_A_B;VA108M;VA107M;SUR;;1FFW_A_B;8.1E-06;8.1E-06;1.2E-06;1.2E-06;7592655;Chemotaxis protein CheY;Chemotaxis protein CheA;298(assumed);;;;;;;;;;;;;;ELISA;1


1FFW_A_B;FA111V;FA110V;INT;;1FFW_A_B;1E-05;1E-05;1.2E-06;1.2E-06;7592655;Chemotaxis protein CheY;Chemotaxis protein CheA;298(assumed);;;;;;;;;;;;;;ELISA;1


1FFW_A_B;TA112I;TA111I;SUR;;1FFW_A_B;3.1E-06;3.1E-06;1.2E-06;1.2E-06;7592655;Chemotaxis protein CheY;Chemotaxis protein CheA;298(assumed);;;;;;;;;;;;;;ELISA;1


1FFW_A_B;EA117K;EA116K;SUR;;1FFW_A_B;4E-06;4E-06;1.2E-06;1.2E-06;7592655;Chemotaxis protein CheY;Chemotaxis protein CheA;298(assumed);;;;;;;;;;;;;;ELISA;1


1DQJ_AB_C;YC20A;YC20A;COR;AB/AG;AB/AG;7.14E-07;7.14E-07;2.78E-09;2.78E-09;10828942;HyHEL-63 fab;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar. This is repeated in 12515535


1DQJ_AB_C;RC21A;RC21A;COR;AB/AG;AB/AG;2E-08;2E-08;2.78E-09;2.78E-09;10828942;HyHEL-63 fab;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar. This is repeated in 12515535


1DQJ_AB_C;WC63A;WC63A;SUP;AB/AG;AB/AG;2.7E-08;2.7E-08;2.78E-09;2.78E-09;10828942;HyHEL-63 fab;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar. This is repeated in 12515535


1DQJ_AB_C;KC97A;KC97A;COR;AB/AG;AB/AG;1.06E-06;1.06E-06;2.78E-09;2.78E-09;10828942;HyHEL-63 fab;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar. This is repeated in 12515535


1DQJ_AB_C;DC101A;DC101A;COR;AB/AG;AB/AG;3.23E-08;3.23E-08;2.78E-09;2.78E-09;10828942;HyHEL-63 fab;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar. This is repeated in 12515535


1DQJ_AB_C;WC62A;WC62A;RIM;AB/AG;AB/AG;1E-08;1E-08;2.78E-09;2.78E-09;12515535;HyHEL-63 fab;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar


SUP;AB/AG;AB/AG;5E-05;5E-05;2.78E-09;2.78E-09;12515535;HyHEL-63 fab;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar


COR;AB/AG;AB/AG;1E-06;1E-06;2.78E-09;2.78E-09;12515535;HyHEL-63 fab;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar


3QHY_A_B;1.25E-06;1.25E-06;5.82E-07;5.82E-07;16809340;SHV-1 beta-lactamase;BLIP;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


3QHY_A_B;1.8E-06;1.8E-06;1.1E-09;1.1E-09;21294157;SHV-1 beta-lactamase;BLIP;299;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


2FTL_E_I;GI12A;GI12A;COR;Pr/PI;Pr/PI;8.3E-11;8.3E-11;5E-14;5E-14;8784199;Bovine trypsin;BPTI;295;2.3E+05;2.3E+05;9.9E+05;9.9E+05;1.9E-05;1.9E-05;5E-08;5E-08;;;;;Asp115 of trypsin is covalently bound to the adjacent residue via a beta-peptide linkage. Modified residue has been removed.


2FTL_E_I;KI15A;KI15A;COR;Pr/PI;Pr/PI;1.4E-06;1.4E-06;5E-14;5E-14;8784199;Bovine trypsin;BPTI;295;4.3E+03;4.3E+03;9.9E+05;9.9E+05;4.2E-05;4.2E-05;5E-08;5E-08;;;;;Asp115 of trypsin is covalently bound to the adjacent residue via a beta-peptide linkage. Modified residue has been removed.


2FTL_E_I;II18A;II18A;COR;Pr/PI;Pr/PI;2.4E-10;2.4E-10;5E-14;5E-14;8784199;Bovine trypsin;BPTI;295;3.9E+05;3.9E+05;9.9E+05;9.9E+05;9.2E-05;9.2E-05;5E-08;5E-08;;;;;Asp115 of trypsin is covalently bound to the adjacent residue via a beta-peptide linkage. Modified residue has been removed.


2FTL_E_I;GI36A;GI36A;SUP;Pr/PI;Pr/PI;2.1E-10;2.1E-10;5E-14;5E-14;8784199;Bovine trypsin;BPTI;295;5.1E+05;5.1E+05;9.9E+05;9.9E+05;1.1E-04;1.1E-04;5E-08;5E-08;;;;;Asp115 of trypsin is covalently bound to the adjacent residue via a beta-peptide linkage. Modified residue has been removed.


2FTL_E_I;KI15G;KI15G;COR;Pr/PI;Pr/PI;6.67E-05;6.67E-05;5.88E-14;5.88E-14;10339415;Bovine trypsin;BPTI;295;;;;;;;;;;;;;Asp115 of trypsin is covalently bound to the adjacent residue via a beta-peptide linkage. Modified residue has been removed.


2FTL_E_I;KI15A;KI15A;COR;Pr/PI;Pr/PI;3.7E-06;3.7E-06;5.88E-14;5.88E-14;10339415;Bovine trypsin;BPTI;295;;;;;;;;;;;;;Asp115 of trypsin is covalently bound to the adjacent residue via a beta-peptide linkage. Modified residue has been removed.


2FTL_E_I;KI15S;KI15S;COR;Pr/PI;Pr/PI;2.7E-08;2.7E-08;5.88E-14;5.88E-14;10339415;Bovine trypsin;BPTI;295;;;;;;;;;;;;;Asp115 of trypsin is covalently bound to the adjacent residue via a beta-peptide linkage. Modified residue has been removed.


2FTL_E_I;KI15V;KI15V;COR;Pr/PI;Pr/PI;2.44E-05;2.44E-05;5.88E-14;5.88E-14;10339415;Bovine trypsin;BPTI;295;;;;;;;;;;;;;Asp115 of trypsin is covalently bound to the adjacent residue via a beta-peptide linkage. Modified residue has been removed.


2FTL_E_I;KI15T;KI15T;COR;Pr/PI;Pr/PI;3.45E-06;3.45E-06;5.88E-14;5.88E-14;10339415;Bovine trypsin;BPTI;295;;;;;;;;;;;;;Asp115 of trypsin is covalently bound to the adjacent residue via a beta-peptide linkage. Modified residue has been removed.


2FTL_E_I;KI15D;KI15D;COR;Pr/PI;Pr/PI;1.59E-05;1.59E-05;5.88E-14;5.88E-14;10339415;Bovine trypsin;BPTI;295;;;;;;;;;;;;;Asp115 of trypsin is covalently bound to the adjacent residue via a beta-peptide linkage. Modified residue has been removed.


2FTL_E_I;KI15N;KI15N;COR;Pr/PI;Pr/PI;4.55E-08;4.55E-08;5.88E-14;5.88E-14;10339415;Bovine trypsin;BPTI;295;;;;;;;;;;;;;Asp115 of trypsin is covalently bound to the adjacent residue via a beta-peptide linkage. Modified residue has been removed.


2FTL_E_I;KI15M;KI15M;COR;Pr/PI;Pr/PI;2.56E-08;2.56E-08;5.88E-14;5.88E-14;10339415;Bovine trypsin;BPTI;295;;;;;;;;;;;;;Asp115 of trypsin is covalently bound to the adjacent residue via a beta-peptide linkage. Modified residue has been removed.


2FTL_E_I;KI15I;KI15I;COR;Pr/PI;Pr/PI;9.09E-06;9.09E-06;5.88E-14;5.88E-14;10339415;Bovine trypsin;BPTI;295;;;;;;;;;;;;;Asp115 of trypsin is covalently bound to the adjacent residue via a beta-peptide linkage. Modified residue has been removed.


2FTL_E_I;KI15L;KI15L;COR;Pr/PI;Pr/PI;1.85E-07;1.85E-07;5.88E-14;5.88E-14;10339415;Bovine trypsin;BPTI;295;;;;;;;;;;;;;Asp115 of trypsin is covalently bound to the adjacent residue via a beta-peptide linkage. Modified residue has been removed.


2FTL_E_I;KI15E;KI15E;COR;Pr/PI;Pr/PI;4.76E-07;4.76E-07;5.88E-14;5.88E-14;10339415;Bovine trypsin;BPTI;295;;;;;;;;;;;;;Asp115 of trypsin is covalently bound to the adjacent residue via a beta-peptide linkage. Modified residue has been removed.


2FTL_E_I;KI15Q;KI15Q;COR;Pr/PI;Pr/PI;4.35E-07;4.35E-07;5.88E-14;5.88E-14;10339415;Bovine trypsin;BPTI;295;;;;;;;;;;;;;Asp115 of trypsin is covalently bound to the adjacent residue via a beta-peptide linkage. Modified residue has been removed.


2FTL_E_I;KI15H;KI15H;COR;Pr/PI;Pr/PI;1.61E-07;1.61E-07;5.88E-14;5.88E-14;10339415;Bovine trypsin;BPTI;295;;;;;;;;;;;;;Asp115 of trypsin is covalently bound to the adjacent residue via a beta-peptide linkage. Modified residue has been removed.


2FTL_E_I;KI15R;KI15R;COR;Pr/PI;Pr/PI;~2.2E-14;2.2E-14;5.88E-14;5.88E-14;10339415;Bovine trypsin;BPTI;295;;;;;;;;;;;;;Asp115 of trypsin is covalently bound to the adjacent residue via a beta-peptide linkage. Modified residue has been removed. Approximate value.;IASP;2


2FTL_E_I;KI15F;KI15F;COR;Pr/PI;Pr/PI;8.33E-09;8.33E-09;5.88E-14;5.88E-14;10339415;Bovine trypsin;BPTI;295;;;;;;;;;;;;;Asp115 of trypsin is covalently bound to the adjacent residue via a beta-peptide linkage. Modified residue has been removed.


2FTL_E_I;KI15Y;KI15Y;COR;Pr/PI;Pr/PI;6.25E-09;6.25E-09;5.88E-14;5.88E-14;10339415;Bovine trypsin;BPTI;295;;;;;;;;;;;;;Asp115 of trypsin is covalently bound to the adjacent residue via a beta-peptide linkage. Modified residue has been removed.


2FTL_E_I;KI15W;KI15W;COR;Pr/PI;Pr/PI;1.32E-07;1.32E-07;5.88E-14;5.88E-14;10339415;Bovine trypsin;BPTI;295;;;;;;;;;;;;;Asp115 of trypsin is covalently bound to the adjacent residue via a beta-peptide linkage. Modified residue has been removed.


which is away from the binding site and doesn't affect binding;SPR;1


1BP3_A_B;8.4E-10;8.4E-10;3.4E-10;3.4E-10;9571026;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;4.1E-10;4.1E-10;3.4E-10;3.4E-10;9571026;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;3.4E-10;3.4E-10;3.4E-10;3.4E-10;9571026;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;2.9E-10;2.9E-10;3.4E-10;3.4E-10;9571026;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding.In paper


1BP3_A_B;3.3E-10;3.3E-10;3.4E-10;3.4E-10;9571026;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;>1E-06;1E-06;3.4E-10;3.4E-10;9571026;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding;SPR;2


1BP3_A_B;5.4E-10;5.4E-10;3.4E-10;3.4E-10;9571026;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;4.6E-10;4.6E-10;3.4E-10;3.4E-10;9571026;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;3.7E-10;3.7E-10;3.4E-10;3.4E-10;9571026;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;4.8E-10;4.8E-10;3.4E-10;3.4E-10;9571026;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;8.2E-10;8.2E-10;3.4E-10;3.4E-10;9571026;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;2.7E-10;2.7E-10;3.4E-10;3.4E-10;9571026;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding;SPR;2


1BP3_A_B;4.5E-10;4.5E-10;3.4E-10;3.4E-10;9571026;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding;SPR;2


1BP3_A_B;1.3E-10;1.3E-10;3.4E-10;3.4E-10;9571026;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding;SPR;2


1BP3_A_B;1.9E-10;1.9E-10;3.4E-10;3.4E-10;9571026;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;7.8E-11;7.8E-11;3.4E-10;3.4E-10;9571026;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding;SPR;2


1BP3_A_B;7.5E-11;7.5E-11;3.4E-10;3.4E-10;9571026;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;3.2E-11;3.2E-11;3.4E-10;3.4E-10;9571026;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding;SPR;2


1BP3_A_B;3.2E-10;3.2E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding;IARA;1


1BP3_A_B;6E-10;6E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding;IARA;1


1BP3_A_B;2E-09;2E-09;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding;IARA;1


1BP3_A_B;5.7E-10;5.7E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;6.8E-10;6.8E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;3.6E-10;3.6E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;4.9E-10;4.9E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding;IARA;1


which is away from the binding site and doesn't affect binding;IARA;1


1BP3_A_B;6.3E-10;6.3E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;3.2E-09;3.2E-09;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;6.4E-10;6.4E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;1.2E-09;1.2E-09;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;8.1E-10;8.1E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;1.1E-09;1.1E-09;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;3.5E-10;3.5E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;5.1E-10;5.1E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;1.5E-09;1.5E-09;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;5.4E-10;5.4E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;4.3E-10;4.3E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;2.1E-09;2.1E-09;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;8E-10;8E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;2.5E-09;2.5E-09;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;4.6E-10;4.6E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;4E-10;4E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;5.6E-10;5.6E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;6E-10;6E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;3.7E-10;3.7E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;3.6E-10;3.6E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;4.4E-10;4.4E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;2.9E-10;2.9E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;9.3E-10;9.3E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;7E-10;7E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;4.8E-10;4.8E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;1E-09;1E-09;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;5.3E-10;5.3E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;>1E-06;1E-06;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding;IARA;2


1BP3_A_B;4.4E-08;4.4E-08;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;6.2E-10;6.2E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;3.9E-10;3.9E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;4.5E-10;4.5E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;1.9E-10;1.9E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;1.5E-10;1.5E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;2.6E-10;2.6E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;2E-10;2E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;2.3E-10;2.3E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;1.7E-10;1.7E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;2.5E-09;2.5E-09;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;8.8E-10;8.8E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;8.3E-10;8.3E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;5E-10;5E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;3.7E-10;3.7E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;3.8E-10;3.8E-10;4E-10;4E-10;2034689;Human growth hormone;hGH binding protein;298;;;;;;;;;;;;;CS is the G120R mutant


which is away from the binding site and doesn't affect binding;SPR;1


which is away from the binding site and doesn't affect binding;ITC;2


1BP3_A_B;3.95E-08;3.95E-08;1E-09;1E-09;7529940;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding. ffinities calculated from ddG taken from ASEdb


1BP3_A_B;2.01E-08;2.01E-08;1E-09;1E-09;7529940;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;1.35E-09;1.35E-09;1E-09;1E-09;7529940;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;1.14E-09;1.14E-09;1E-09;1E-09;7529940;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;1E-09;1E-09;1E-09;1E-09;7529940;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;8.13E-10;8.13E-10;1E-09;1E-09;7529940;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;2.65E-09;2.65E-09;1E-09;1E-09;7529940;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;6.87E-10;6.87E-10;1E-09;1E-09;7529940;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;2.82E-08;2.82E-08;1E-09;1E-09;7529940;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;5.21E-09;5.21E-09;1E-09;1E-09;7529940;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;1.43E-08;1.43E-08;1E-09;1E-09;7529940;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;2.95E-10;2.95E-10;1E-09;1E-09;7529940;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;4.4E-09;4.4E-09;1E-09;1E-09;7529940;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;1.6E-09;1.6E-09;1E-09;1E-09;7529940;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;3.1E-10;3.1E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding;RA;2


1BP3_A_B;6.8E-10;6.8E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;7.1E-10;7.1E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;1E-09;1E-09;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;6.1E-10;6.1E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;4.8E-10;4.8E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;3.2E-10;3.2E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;2E-09;2E-09;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;4E-10;4E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;7.5E-10;7.5E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;4.4E-10;4.4E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;5.1E-10;5.1E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;2.4E-10;2.4E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;3.7E-10;3.7E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;1.5E-09;1.5E-09;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;4.1E-10;4.1E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;1.4E-09;1.4E-09;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;5.6E-09;5.6E-09;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;6.5E-10;6.5E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;2E-10;2E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;7.1E-10;7.1E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;1.8E-09;1.8E-09;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;3.1E-10;3.1E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;8.2E-10;8.2E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;6.8E-10;6.8E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;2.6E-10;2.6E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;2.4E-09;2.4E-09;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;4.6E-09;4.6E-09;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;7.5E-11;7.5E-11;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;5.9E-09;5.9E-09;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;5.4E-09;5.4E-09;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;2.9E-09;2.9E-09;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;9.2E-10;9.2E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;3.4E-10;3.4E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;5.4E-10;5.4E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;1.9E-09;1.9E-09;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;1.5E-09;1.5E-09;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;2.7E-10;2.7E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;6.1E-10;6.1E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;2.4E-10;2.4E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;4.7E-10;4.7E-10;3.4E-10;3.4E-10;2471267;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;5.8E-10;5.8E-10;3.4E-10;3.4E-10;2321008;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;2E-10;2E-10;3.4E-10;3.4E-10;2321008;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;2.9E-09;2.9E-09;3.4E-10;3.4E-10;2321008;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;1.7E-09;1.7E-09;3.4E-10;3.4E-10;2321008;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;1.4E-09;1.4E-09;3.4E-10;3.4E-10;2466339;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding;RA;2


1BP3_A_B;1.2E-09;1.2E-09;3.4E-10;3.4E-10;2466339;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding;RA;2


1BP3_A_B;3.6E-09;3.6E-09;3.4E-10;3.4E-10;2466339;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding;RA;2


1BP3_A_B;5.8E-09;5.8E-09;3.4E-10;3.4E-10;2466339;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding;RA;2


1BP3_A_B;2.9E-10;2.9E-10;3.4E-10;3.4E-10;2466339;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding;RA;2


1BP3_A_B;2.5E-09;2.5E-09;3.4E-10;3.4E-10;2466339;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;9.4E-10;9.4E-10;3.4E-10;3.4E-10;2466339;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding;RA;2


1BP3_A_B;1E-08;1E-08;3.4E-10;3.4E-10;2466339;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;5.8E-09;5.8E-09;3.4E-10;3.4E-10;2466339;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;2.3E-08;2.3E-08;3.4E-10;3.4E-10;2466339;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding;RA;2


1BP3_A_B;4.7E-10;4.7E-10;3.4E-10;3.4E-10;2466339;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1BP3_A_B;5.3E-10;5.3E-10;3.4E-10;3.4E-10;2466339;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding;RA;2


1BP3_A_B;6.1E-10;6.1E-10;3.4E-10;3.4E-10;2466339;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding;RA;2


1BP3_A_B;5.2E-10;5.2E-10;3.4E-10;3.4E-10;2466339;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding

GA120L is removed from the list of mutations.;RA;2


TA135N are not included as they appear in a disordered region;RA;2

1BP3_A_B;5.8E-10;5.8E-10;3.4E-10;3.4E-10;2466339;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding.DA130P


1BP3_A_B;9.2E-09;9.2E-09;3.4E-10;3.4E-10;2466339;Human growth hormone;hGH binding protein;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


which is away from the binding site and doesn't affect binding;RA;2


1A22_A_B;5E-11;5E-11;3.3E-11;3.3E-11;2014261;Human growth hormone;Prolactin receptor;298(assumed);;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding;RA;2


which is away from the binding site and doesn't affect binding;RA;2

1A22_A_B;7E-11;7E-11;3.3E-11;3.3E-11;2014261;Human growth hormone;Prolactin receptor;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1A22_A_B;5E-10;5E-10;3.3E-11;3.3E-11;2014261;Human growth hormone;Prolactin receptor;298(assumed);;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding;RA;2


1A22_A_B;6E-11;6E-11;3.3E-11;3.3E-11;2014261;Human growth hormone;Prolactin receptor;298(assumed);;;;;;;;;;;;;CS is the G120R mutant

which is away from the binding site and doesn't affect binding;RA;2


1A22_A_B;2E-11;2E-11;3.3E-11;3.3E-11;2014261;Human growth hormone;Prolactin receptor;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1A22_A_B;3E-09;3E-09;3.3E-11;3.3E-11;2014261;Human growth hormone;Prolactin receptor;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1A22_A_B;5E-11;5E-11;3.3E-11;3.3E-11;2014261;Human growth hormone;Prolactin receptor;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1A22_A_B;6E-11;6E-11;3.3E-11;3.3E-11;2014261;Human growth hormone;Prolactin receptor;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1A22_A_B;4E-11;4E-11;3.3E-11;3.3E-11;2014261;Human growth hormone;Prolactin receptor;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1A22_A_B;7E-11;7E-11;3.3E-11;3.3E-11;2014261;Human growth hormone;Prolactin receptor;298(assumed);;;;;;;;;;;;;CS is the G120R mutant


1A22_A_B;3.7E-07;3.7E-07;2.7E-07;2.7E-07;2014261;Human growth hormone;Prolactin receptor;298(assumed);;;;;;;;;;;;;Absence of zinc


1A22_A_B;2E-07;2E-07;2.7E-07;2.7E-07;2014261;Human growth hormone;Prolactin receptor;298(assumed);;;;;;;;;;;;;Absence of zinc


1A22_A_B;5.5E-06;5.5E-06;2.7E-07;2.7E-07;2014261;Human growth hormone;Prolactin receptor;298(assumed);;;;;;;;;;;;;Absence of zinc


1A22_A_B;9.7E-06;9.7E-06;2.7E-07;2.7E-07;2014261;Human growth hormone;Prolactin receptor;298(assumed);;;;;;;;;;;;;Absence of zinc


1A22_A_B;8.2E-06;8.2E-06;2.7E-07;2.7E-07;2014261;Human growth hormone;Prolactin receptor;298(assumed);;;;;;;;;;;;;Absence of zinc


1A22_A_B;3.6E-07;3.6E-07;2.7E-07;2.7E-07;2014261;Human growth hormone;Prolactin receptor;298(assumed);;;;;;;;;;;;;Absence of zinc


1A22_A_B;7.2E-06;7.2E-06;2.7E-07;2.7E-07;2014261;Human growth hormone;Prolactin receptor;298(assumed);;;;;;;;;;;;;Absence of zinc


1BP3_A_B;8.4E-06;8.4E-06;7.2E-06;7.2E-06;20889499;Prolactin;Prolactin receptor;298;8E+03;8E+03;1.7E+04;1.7E+04;7E-02;7E-02;1.2E-01;1.2E-01;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. PH 5.75.;SPR;2


1BP3_A_B;1.3E-08;1.3E-08;1.6E-08;1.6E-08;20889499;Prolactin;Prolactin receptor;298;9E+04;9E+04;1.1E+05;1.1E+05;1.2E-03;1.2E-03;1.7E-03;1.7E-03;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. PH 7.5;SPR;2


1BP3_A_B;1.1E-08;1.1E-08;1.9E-08;1.9E-08;20889499;Prolactin;Prolactin receptor;298;8.8E+04;8.8E+04;9.2E+04;9.2E+04;1E-03;1E-03;1.8E-03;1.8E-03;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. pH 8;SPR;2


1BP3_A_B;8.4E-06;8.4E-06;1.92E-06;1.92E-06;20889499;Prolactin;Prolactin receptor;298;8E+03;8E+03;2.2E+04;2.2E+04;7E-02;7E-02;4.3E-02;4.3E-02;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. PH 5.75.;SPR;2


1BP3_A_B;3.3E-08;3.3E-08;5.3E-08;5.3E-08;20889499;Prolactin;Prolactin receptor;298;8.7E+04;8.7E+04;9.6E+04;9.6E+04;2.9E-03;2.9E-03;5.1E-03;5.1E-03;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. PH 7;SPR;2


1BP3_A_B;1.3E-08;1.3E-08;2.4E-08;2.4E-08;20889499;Prolactin;Prolactin receptor;298;9E+04;9E+04;9.9E+04;9.9E+04;1.2E-03;1.2E-03;2.4E-03;2.4E-03;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. PH 7.5;SPR;2


1BP3_A_B;1.1E-08;1.1E-08;2.1E-08;2.1E-08;20889499;Prolactin;Prolactin receptor;298;9.4E+04;9.4E+04;9.9E+04;9.9E+04;1E-03;1E-03;2.1E-03;2.1E-03;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. PH 7.75;SPR;2


1BP3_A_B;1.1E-08;1.1E-08;1.9E-08;1.9E-08;20889499;Prolactin;Prolactin receptor;298;8.8E+04;8.8E+04;9.4E+04;9.4E+04;1E-03;1E-03;1.8E-03;1.8E-03;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. pH 8;SPR;2


1BP3_A_B;8.4E-06;8.4E-06;1.32E-05;1.32E-05;20889499;Prolactin;Prolactin receptor;298;8E+03;8E+03;4E+04;4E+04;7E-02;7E-02;6E-01;6E-01;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. PH 5.75.;SPR;2


1BP3_A_B;2.13E-06;2.13E-06;7.9E-06;7.9E-06;20889499;Prolactin;Prolactin receptor;298;7.4E+03;7.4E+03;5E+04;5E+04;1.58E-02;1.58E-02;4E-01;4E-01;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. PH 6;SPR;2


1BP3_A_B;7.7E-08;7.7E-08;2.4E-06;2.4E-06;20889499;Prolactin;Prolactin receptor;298;7.5E+04;7.5E+04;7E+04;7E+04;5.8E-03;5.8E-03;1.7E-01;1.7E-01;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. PH 6.75;SPR;2


1BP3_A_B;1.3E-08;1.3E-08;8.2E-07;8.2E-07;20889499;Prolactin;Prolactin receptor;298;9E+04;9E+04;6E+04;6E+04;1.2E-03;1.2E-03;4.9E-02;4.9E-02;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. PH 7.5;SPR;2


1BP3_A_B;1.1E-08;1.1E-08;5.1E-07;5.1E-07;20889499;Prolactin;Prolactin receptor;298;9.4E+04;9.4E+04;8.7E+04;8.7E+04;1E-03;1E-03;4.4E-02;4.4E-02;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. PH 7.75;SPR;2


1BP3_A_B;1.1E-08;1.1E-08;4.6E-07;4.6E-07;20889499;Prolactin;Prolactin receptor;298;8.8E+04;8.8E+04;8.5E+04;8.5E+04;1E-03;1E-03;3.9E-02;3.9E-02;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. pH 8;SPR;2


1BP3_A_B;2E-05;2E-05;9.4E-06;9.4E-06;20889499;Prolactin;Prolactin receptor;298;2E+03;2E+03;3.4E+04;3.4E+04;4.5E-02;4.5E-02;3.22E-01;3.22E-01;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. PH 6;SPR;2


SUR;AB/AG;AB/AG;4.14E-08;4.14E-08;1.42E-08;1.42E-08;9367779;mAbs A6;Interferon gamma receptor;298;;;;;;;;;;;;;The mutant also contains RI106L and DI107K mutations

but these are disordered in the crystal structure


COR;;1DAN_HL_UT;3.17E-11;3.17E-11;2.6E-12;2.6E-12;7756258;Factor VIIa;Tissue factor;310;;;;;;;;;;;;;Apparent affinity. Crystal structure contained non-interfacial carboxyglutamic acid residues

which have been reverted back to glutamic acids.


1DAN_HL_UT;WT45A;WT40A;COR;;1DAN_HL_UT;3.27E-11;3.27E-11;2.6E-12;2.6E-12;7756258;Factor VIIa;Tissue factor;310;;;;;;;;;;;;;Apparent affinity. Crystal structure contained non-interfacial carboxyglutamic acid residues

which have been reverted back to glutamic acids.


1DAN_HL_UT;ST47A;ST42A;COR;;1DAN_HL_UT;2.1E-12;2.1E-12;2.6E-12;2.6E-12;7756258;Factor VIIa;Tissue factor;310;;;;;;;;;;;;;Apparent affinity. Crystal structure contained non-interfacial carboxyglutamic acid residues


1DAN_HL_UT;VT33A;VT28A;INT;;1DAN_HL_UT;1.9E-12;1.9E-12;2.6E-12;2.6E-12;7756258;Factor VIIa;Tissue factor;310;;;;;;;;;;;;;Apparent affinity. Crystal structure contained non-interfacial carboxyglutamic acid residues


1DAN_HL_UT;YT51A;YT46A;RIM;;1DAN_HL_UT;2.1E-12;2.1E-12;2.6E-12;2.6E-12;7756258;Factor VIIa;Tissue factor;310;;;;;;;;;;;;;Apparent affinity. Crystal structure contained non-interfacial carboxyglutamic acid residues


1DAN_HL_UT;FT76A;FT71A;SUP;;1DAN_HL_UT;1.68E-11;1.68E-11;2.6E-12;2.6E-12;7756258;Factor VIIa;Tissue factor;310;;;;;;;;;;;;;Apparent affinity. Crystal structure contained non-interfacial carboxyglutamic acid residues


1DAN_HL_UT;YT78A;YT73A;RIM;;1DAN_HL_UT;7.5E-12;7.5E-12;2.6E-12;2.6E-12;7756258;Factor VIIa;Tissue factor;310;;;;;;;;;;;;;Apparent affinity. Crystal structure contained non-interfacial carboxyglutamic acid residues


1DAN_HL_UT;PU92A;PU2A;RIM;;1DAN_HL_UT;1.9E-12;1.9E-12;2.6E-12;2.6E-12;7756258;Factor VIIa;Tissue factor;310;;;;;;;;;;;;;Apparent affinity. Crystal structure contained non-interfacial carboxyglutamic acid residues


1DAN_HL_UT;YU94A;YU4A;COR;;1DAN_HL_UT;4.4E-12;4.4E-12;2.6E-12;2.6E-12;7756258;Factor VIIa;Tissue factor;310;;;;;;;;;;;;;Apparent affinity. Crystal structure contained non-interfacial carboxyglutamic acid residues


1DAN_HL_UT;VT36A;VT31A;INT;;1DAN_HL_UT;2.1E-12;2.1E-12;2.6E-12;2.6E-12;7756258;Factor VIIa;Tissue factor;310;;;;;;;;;;;;;Apparent affinity. Crystal structure contained non-interfacial carboxyglutamic acid residues


1DAN_HL_UT;QT37A;QT32A;SUP;;1DAN_HL_UT;8.9E-12;8.9E-12;2.6E-12;2.6E-12;7756258;Factor VIIa;Tissue factor;310;;;;;;;;;;;;;Apparent affinity. Crystal structure contained non-interfacial carboxyglutamic acid residues


1DAN_HL_UT;IT38A;IT33A;INT;;1DAN_HL_UT;2.1E-12;2.1E-12;2.6E-12;2.6E-12;7756258;Factor VIIa;Tissue factor;310;;;;;;;;;;;;;Apparent affinity. Crystal structure contained non-interfacial carboxyglutamic acid residues


1DAN_HL_UT;GT43A;GT38A;COR;;1DAN_HL_UT;2.9E-12;2.9E-12;2.6E-12;2.6E-12;7756258;Factor VIIa;Tissue factor;310;;;;;;;;;;;;;Apparent affinity. Crystal structure contained non-interfacial carboxyglutamic acid residues


1DAN_HL_UT;KT48A;KT43A;SUP;;1DAN_HL_UT;1.23E-11;1.23E-11;2.6E-12;2.6E-12;7756258;Factor VIIa;Tissue factor;310;;;;;;;;;;;;;Apparent affinity. Crystal structure contained non-interfacial carboxyglutamic acid residues


INT;;1DAN_HL_UT;1.5E-12;1.5E-12;2.6E-12;2.6E-12;7756258;Factor VIIa;Tissue factor;310;;;;;;;;;;;;;Apparent affinity. Crystal structure contained non-interfacial carboxyglutamic acid residues


1DAN_HL_UT;TT60A;TT55A;INT;;1DAN_HL_UT;1.11E-10;1.11E-10;2.6E-12;2.6E-12;7756258;Factor VIIa;Tissue factor;310;;;;;;;;;;;;;Apparent affinity. Crystal structure contained non-interfacial carboxyglutamic acid residues


COR;;1DAN_HL_UT;3.85E-09;3.85E-09;2.6E-12;2.6E-12;7756258;Factor VIIa;Tissue factor;310;;;;;;;;;;;;;Apparent affinity. Crystal structure contained non-interfacial carboxyglutamic acid residues


COR;;1DAN_HL_UT;4.51E-10;4.51E-10;2.6E-12;2.6E-12;7756258;Factor VIIa;Tissue factor;310;;;;;;;;;;;;;Apparent affinity. Crystal structure contained non-interfacial carboxyglutamic acid residues


1DAN_HL_UT;DT44A;DT39A;RIM;;1DAN_HL_UT;2.67E-11;2.67E-11;2.6E-12;2.6E-12;7756258;Factor VIIa;Tissue factor;310;;;;;;;;;;;;;Apparent affinity. Crystal structure contained non-interfacial carboxyglutamic acid residues


COR;;1DAN_HL_UT;3.31E-11;3.31E-11;2.6E-12;2.6E-12;7756258;Factor VIIa;Tissue factor;310;;;;;;;;;;;;;Apparent affinity. Crystal structure contained non-interfacial carboxyglutamic acid residues


COR;;1DAN_HL_UT;5.51E-10;5.51E-10;2.6E-12;2.6E-12;7756258;Factor VIIa;Tissue factor;310;;;;;;;;;;;;;Apparent affinity. Crystal structure contained non-interfacial carboxyglutamic acid residues


COR;;1DAN_HL_UT;2.21E-09;2.21E-09;2.6E-12;2.6E-12;7756258;Factor VIIa;Tissue factor;310;;;;;;;;;;;;;Apparent affinity. Crystal structure contained non-interfacial carboxyglutamic acid residues


COR;;1DAN_HL_UT;1.75E-09;1.75E-09;2.6E-12;2.6E-12;7756258;Factor VIIa;Tissue factor;310;;;;;;;;;;;;;Apparent affinity. Crystal structure contained non-interfacial carboxyglutamic acid residues


INT;;1DAN_HL_UT;2.91E-09;2.91E-09;2.6E-12;2.6E-12;7756258;Factor VIIa;Tissue factor;310;;;;;;;;;;;;;Apparent affinity. Crystal structure contained non-interfacial carboxyglutamic acid residues


COR;;1DAN_HL_UT;4.16E-08;4.16E-08;2.6E-12;2.6E-12;7756258;Factor VIIa;Tissue factor;310;;;;;;;;;;;;;Apparent affinity. Crystal structure contained non-interfacial carboxyglutamic acid residues

which have been reverted back to glutamic acids.


1DAN_HL_UT;RH134A;RH125A;COR;;1DAN_HL_UT;1.31E-08;1.31E-08;3.7E-09;3.7E-09;8962059;Factor VIIa;Tissue factor;296;1.4E+05;1.4E+05;1.6E+05;1.6E+05;1.8E-03;1.8E-03;5.7E-04;5.7E-04;;;;;Crystal structure contained non-interfacial carboxyglutamic acid residues


1DAN_HL_UT;MH164A;MH154A;COR;;1DAN_HL_UT;1.3E-08;1.3E-08;3.7E-09;3.7E-09;8962059;Factor VIIa;Tissue factor;296;1.2E+05;1.2E+05;1.6E+05;1.6E+05;1.5E-03;1.5E-03;5.7E-04;5.7E-04;;;;;Crystal structure contained non-interfacial carboxyglutamic acid residues


1DAN_HL_UT;KH192A;KH189A;SUR;;1DAN_HL_UT;2.7E-09;2.7E-09;3.7E-09;3.7E-09;8962059;Factor VIIa;Tissue factor;296;1.5E+05;1.5E+05;1.6E+05;1.6E+05;3.9E-04;3.9E-04;5.7E-04;5.7E-04;;;;;Crystal structure contained non-interfacial carboxyglutamic acid residues


1DAN_HL_UT;LH144A;LH135A;SUR;;1DAN_HL_UT;3.8E-09;3.8E-09;3.7E-09;3.7E-09;8962059;Factor VIIa;Tissue factor;296;1.5E+05;1.5E+05;1.6E+05;1.6E+05;5.7E-04;5.7E-04;5.7E-04;5.7E-04;;;;;Crystal structure contained non-interfacial carboxyglutamic acid residues


1DAN_HL_UT;KT20A;KT15A;COR;;1DAN_HL_UT;3.25E-07;3.25E-07;5.3E-09;5.3E-09;7947809;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Crystal structure contained non-interfacial carboxyglutamic acid residues


1DAN_HL_UT;DT44A;DT39A;RIM;;1DAN_HL_UT;1.98E-07;1.98E-07;5.3E-09;5.3E-09;7947809;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Crystal structure contained non-interfacial carboxyglutamic acid residues


1DAN_HL_UT;WT45A;WT40A;COR;;1DAN_HL_UT;2.9E-07;2.9E-07;5.3E-09;5.3E-09;7947809;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Crystal structure contained non-interfacial carboxyglutamic acid residues


1DAN_HL_UT;KT46A;KT41A;COR;;1DAN_HL_UT;2.4E-08;2.4E-08;5.3E-09;5.3E-09;7947809;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Crystal structure contained non-interfacial carboxyglutamic acid residues


1DAN_HL_UT;QU110A;QU20A;COR;;1DAN_HL_UT;4.8E-08;4.8E-08;5.3E-09;5.3E-09;7947809;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Crystal structure contained non-interfacial carboxyglutamic acid residues


1DAN_HL_UT;RU135A;RU45A;RIM;;1DAN_HL_UT;2.8E-08;2.8E-08;5.3E-09;5.3E-09;7947809;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Crystal structure contained non-interfacial carboxyglutamic acid residues


1DAN_HL_UT;FU140A;FU50A;COR;;1DAN_HL_UT;2.23E-07;2.23E-07;5.3E-09;5.3E-09;7947809;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Crystal structure contained non-interfacial carboxyglutamic acid residues


1DAN_HL_UT;VU207A;VU113A;COR;;1DAN_HL_UT;7.5E-08;7.5E-08;5.3E-09;5.3E-09;7947809;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Crystal structure contained non-interfacial carboxyglutamic acid residues


1DAN_HL_UT;ST16A;ST11A;INT;;1DAN_HL_UT;6.94E-09;6.94E-09;8.64E-09;8.64E-09;8312277;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Affinities calculated from ddG taken from ASEdb

assuming wt dG of -11. Crystal structure contained non-interfacial carboxyglutamic acid residues

which have been reverted back to glutamic acids.


1DAN_HL_UT;LT59A;LT54A;INT;;1DAN_HL_UT;8.64E-09;8.64E-09;8.64E-09;8.64E-09;8312277;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Affinities calculated from ddG taken from ASEdb


1DAN_HL_UT;DT61A;DT56A;COR;;1DAN_HL_UT;1.3E-08;1.3E-08;8.64E-09;8.64E-09;8312277;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Affinities calculated from ddG taken from ASEdb


1DAN_HL_UT;ET62A;ET57A;SUP;;1DAN_HL_UT;8.64E-09;8.64E-09;8.64E-09;8.64E-09;8312277;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Affinities calculated from ddG taken from ASEdb


1DAN_HL_UT;IT63A;IT58A;INT;;1DAN_HL_UT;8.64E-09;8.64E-09;8.64E-09;8.64E-09;8312277;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Affinities calculated from ddG taken from ASEdb


1DAN_HL_UT;VT64A;VT59A;INT;;1DAN_HL_UT;8.64E-09;8.64E-09;8.64E-09;8.64E-09;8312277;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Affinities calculated from ddG taken from ASEdb


1DAN_HL_UT;QT69A;QT64A;SUR;;1DAN_HL_UT;8.64E-09;8.64E-09;8.64E-09;8.64E-09;8312277;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Affinities calculated from ddG taken from ASEdb


1DAN_HL_UT;LT72A;LT67A;INT;;1DAN_HL_UT;7.81E-09;7.81E-09;8.64E-09;8.64E-09;8312277;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Affinities calculated from ddG taken from ASEdb


1DAN_HL_UT;EU105A;EU15A;SUR;;1DAN_HL_UT;7.81E-09;7.81E-09;8.64E-09;8.64E-09;8312277;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Affinities calculated from ddG taken from ASEdb


1DAN_HL_UT;TU106A;TU16A;INT;;1DAN_HL_UT;7.81E-09;7.81E-09;8.64E-09;8.64E-09;8312277;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Affinities calculated from ddG taken from ASEdb


1DAN_HL_UT;NU107A;NU17A;SUR;;1DAN_HL_UT;8.64E-09;8.64E-09;8.64E-09;8.64E-09;8312277;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Affinities calculated from ddG taken from ASEdb


1DAN_HL_UT;RU131A;RU41A;RIM;;1DAN_HL_UT;8.64E-09;8.64E-09;8.64E-09;8.64E-09;8312277;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Affinities calculated from ddG taken from ASEdb


1DAN_HL_UT;TU132A;TU42A;SUP;;1DAN_HL_UT;8.64E-09;8.64E-09;8.64E-09;8.64E-09;8312277;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Affinities calculated from ddG taken from ASEdb


1DAN_HL_UT;RU136A;RU46A;SUR;;1DAN_HL_UT;7.81E-09;7.81E-09;8.64E-09;8.64E-09;8312277;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Affinities calculated from ddG taken from ASEdb


1DAN_HL_UT;NU138A;NU48A;RIM;;1DAN_HL_UT;8.64E-09;8.64E-09;8.64E-09;8.64E-09;8312277;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Affinities calculated from ddG taken from ASEdb


1DAN_HL_UT;VU146A;VU56A;INT;;1DAN_HL_UT;1.21E-08;1.21E-08;8.64E-09;8.64E-09;8312277;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Affinities calculated from ddG taken from ASEdb


1DAN_HL_UT;FU147A;FU57A;INT;;1DAN_HL_UT;7.81E-09;7.81E-09;8.64E-09;8.64E-09;8312277;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Affinities calculated from ddG taken from ASEdb


1DAN_HL_UT;YU157A;YU67A;INT;;1DAN_HL_UT;8.64E-09;8.64E-09;8.64E-09;8.64E-09;8312277;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Affinities calculated from ddG taken from ASEdb


1DAN_HL_UT;VU179A;VU85A;INT;;1DAN_HL_UT;1.04E-08;1.04E-08;8.64E-09;8.64E-09;8312277;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Affinities calculated from ddG taken from ASEdb


1DAN_HL_UT;RU196A;RU102A;INT;;1DAN_HL_UT;1.88E-08;1.88E-08;8.64E-09;8.64E-09;8312277;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Affinities calculated from ddG taken from ASEdb


1DAN_HL_UT;TU197A;TU103A;SUR;;1DAN_HL_UT;1.04E-08;1.04E-08;8.64E-09;8.64E-09;8312277;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Affinities calculated from ddG taken from ASEdb


1DAN_HL_UT;VU198A;VU104A;SUR;;1DAN_HL_UT;1.04E-08;1.04E-08;8.64E-09;8.64E-09;8312277;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Affinities calculated from ddG taken from ASEdb


1DAN_HL_UT;NU199A;NU105A;SUR;;1DAN_HL_UT;8.64E-09;8.64E-09;8.64E-09;8.64E-09;8312277;Factor VIIa;Tissue factor;298(assumed);;;;;;;;;;;;;Affinities calculated from ddG taken from ASEdb


SUP;AB/AG;AB/AG;n.b;;3E-11;3E-11;10338006;HyHEL-10;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar


3HFM_HL_Y;KY96A;KY96A;SUP;AB/AG;AB/AG;4E-06;4E-06;3E-11;3E-11;10338006;HyHEL-10;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar


3HFM_HL_Y;NL31A;NL31A;COR;AB/AG;AB/AG;2E-07;2E-07;3E-11;3E-11;10338006;HyHEL-10;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar


SUP;AB/AG;AB/AG;9E-06;9E-06;3E-11;3E-11;10338006;HyHEL-10;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar


3HFM_HL_Y;NL31E;NL31E;COR;AB/AG;AB/AG;4.6E-07;4.6E-07;3E-11;3E-11;10338006;HyHEL-10;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar


3HFM_HL_Y;YL50A;YL50A;COR;AB/AG;AB/AG;6.6E-08;6.6E-08;3E-11;3E-11;10338006;HyHEL-10;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar


3HFM_HL_Y;YL50L;YL50L;COR;AB/AG;AB/AG;5E-08;5E-08;3E-11;3E-11;10338006;HyHEL-10;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar


COR;AB/AG;AB/AG;7E-06;7E-06;3E-11;3E-11;10338006;HyHEL-10;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar


COR;AB/AG;AB/AG;n.b;;3E-11;3E-11;10338006;HyHEL-10;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar


3HFM_HL_Y;KY97A;KY97A;COR;AB/AG;AB/AG;1E-06;1E-06;3E-11;3E-11;10338006;HyHEL-10;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar


3HFM_HL_Y;YH33A;YH33A;COR;AB/AG;AB/AG;8E-07;8E-07;3E-11;3E-11;10338006;HyHEL-10;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar


COR;AB/AG;AB/AG;6E-06;6E-06;3E-11;3E-11;10338006;HyHEL-10;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar


3HFM_HL_Y;WH98F;WH98F;COR;AB/AG;AB/AG;7.2E-09;7.2E-09;3E-11;3E-11;10338006;HyHEL-10;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar


3HFM_HL_Y;WH98A;WH98A;COR;AB/AG;AB/AG;3.3E-07;3.3E-07;3E-11;3E-11;10338006;HyHEL-10;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar


COR;AB/AG;AB/AG;7E-08;7E-08;3E-11;3E-11;10338006;HyHEL-10;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar


3HFM_HL_Y;YH50A;YH50A;SUP;AB/AG;AB/AG;7E-06;7E-06;3E-11;3E-11;10338006;HyHEL-10;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar


COR;AB/AG;AB/AG;2E-05;2E-05;3E-11;3E-11;10338006;HyHEL-10;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar


COR;AB/AG;AB/AG;5E-07;5E-07;3E-11;3E-11;10338006;HyHEL-10;HEW Lysozyme;298(assumed);;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar


3HFM_HL_Y;KY96A;KY96A;SUP;AB/AG;AB/AG;>4E-06;4E-06;7E-11;7E-11;9761468;HyHEL-10;HEW Lysozyme;298;;;;;;;;;;;;;NB) HyHEL-10 and HyHEL-63 are very similar


1CHO_EFG_I;LI18G;LI15G;COR;Pr/PI;Pr/PI;1.52E-07;1.52E-07;5.26E-12;5.26E-12;9047374;Bovine alpha-chymotrypsin;Turkey ovomucoid third domain;294;;;;;;;;;;;;;P1. Data was provided by Mohammad A Qasim.


1CHO_EFG_I;LI18A;LI15A;COR;Pr/PI;Pr/PI;1.64E-08;1.64E-08;5.26E-12;5.26E-12;9047374;Bovine alpha-chymotrypsin;Turkey ovomucoid third domain;294;;;;;;;;;;;;;P1. Data was provided by Mohammad A Qasim.


1CHO_EFG_I;LI18S;LI15S;COR;Pr/PI;Pr/PI;2.38E-08;2.38E-08;5.26E-12;5.26E-12;9047374;Bovine alpha-chymotrypsin;Turkey ovomucoid third domain;294;;;;;;;;;;;;;P1. Data was provided by Mohammad A Qasim.


1CHO_EFG_I;LI18C;LI15C;COR;Pr/PI;Pr/PI;4.55E-10;4.55E-10;5.26E-12;5.26E-12;9047374;Bovine alpha-chymotrypsin;Turkey ovomucoid third domain;294;;;;;;;;;;;;;P1. Data was provided by Mohammad A Qasim.


1CHO_EFG_I;LI18V;LI15V;COR;Pr/PI;Pr/PI;7.14E-09;7.14E-09;5.26E-12;5.26E-12;9047374;Bovine alpha-chymotrypsin;Turkey ovomucoid third domain;294;;;;;;;;;;;;;P1. Data was provided by Mohammad A Qasim.


1CHO_EFG_I;LI18T;LI15T;COR;Pr/PI;Pr/PI;1.02E-08;1.02E-08;5.26E-12;5.26E-12;9047374;Bovine alpha-chymotrypsin;Turkey ovomucoid third domain;294;;;;;;;;;;;;;P1. Data was provided by Mohammad A Qasim.


1CHO_EFG_I;LI18P;LI15P;COR;Pr/PI;Pr/PI;1.49E-05;1.49E-05;5.26E-12;5.26E-12;9047374;Bovine alpha-chymotrypsin;Turkey ovomucoid third domain;294;;;;;;;;;;;;;P1. Data was provided by Mohammad A Qasim.